Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare Products Regulatory Agency has assessed the (a) safety and (b) quality of unlicensed cannabis-based products for medicinal use.
Answered by Nadine Dorries
It has not proved possible to respond to the hon. Member in the time available before Dissolution.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether there are circumstances under which Specialist Importers of cannabis-based products for medicinal use are permitted to import that product in bulk.
Answered by Nadine Dorries
It has not proved possible to respond to the hon. Member in the time available before Dissolution.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether there are circumstances under which Specialist Importers may import cannabis-based active pharmaceutical ingredients for use in manufacturing of cannabis-based products for medicinal use in the UK.
Answered by Nadine Dorries
It has not proved possible to respond to the hon. Member in the time available before Dissolution.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many notifications the Medicines and Healthcare products Regulatory Agency received from pharmacies and specials importers on importation orders for unlicensed cannabis-based products for medicinal use in the past 12 months.
Answered by Nadine Dorries
It has not proved possible to respond to the hon. Member in the time available before Dissolution.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to publish his Department's response to the consultation on the regulation of medical associate professions in the UK.
Answered by Steve Barclay - Secretary of State for Environment, Food and Rural Affairs
The Government is committed to supporting the development of a modern health and care workforce as part of the continuing drive to provide safe, accessible and high quality care for patients and service users. A key part of this is ensuring that proportionate assurance processes are in place for both existing and new roles.
As my Rt. hon. Friend the Secretary of State for Health and Social Care announced on the Department’s Talk Health and Care online platform on Friday 12 October, we will be introducing statutory regulation for physician associates and physicians’ assistants (anesthesia). In taking this forward, we will look to develop a framework to which other Medical Associate Professions could be added at a later date as the case arises.
The Department will be publishing its full response to the consultation shortly.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the gap between demand and funding for health services for disabled children and their families; what steps he is taking to address any such gap; and if he will make a statement.
Answered by Caroline Dinenage
The commissioning of health and social care services for children with disabilities is the responsibility of clinical commissioning groups and local authorities respectively. Local commissioners are best placed to assess the needs of the local population, and to mitigate any shortfalls.
In 2014, the Government introduced a new statutory framework requiring local authorities and clinical commissioning groups to commission jointly services for children with special educational needs and disability, across health, social care and education. Since 2014, £327 million has been given to local areas to support implementation of these new arrangements, in addition to the high needs budget for placements for pupils with complex special educational needs which is £6 billion this year, the highest it has ever been.
Every local area’s arrangements are being inspected jointly by Ofsted and the Care Quality Commission, in addition to their role inspecting providers.
There are no plans to establish a disabled children’s fund. Funding for the National Health Service will grow on average by 3.4% in real terms each year from 2019/20 to 2023/24; by 2023/24 the NHS budget will increase by over £20 billion a year in real terms compared with today.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will establish a disabled children’s fund to improve health services for disabled children.
Answered by Caroline Dinenage
The commissioning of health and social care services for children with disabilities is the responsibility of clinical commissioning groups and local authorities respectively. Local commissioners are best placed to assess the needs of the local population, and to mitigate any shortfalls.
In 2014, the Government introduced a new statutory framework requiring local authorities and clinical commissioning groups to commission jointly services for children with special educational needs and disability, across health, social care and education. Since 2014, £327 million has been given to local areas to support implementation of these new arrangements, in addition to the high needs budget for placements for pupils with complex special educational needs which is £6 billion this year, the highest it has ever been.
Every local area’s arrangements are being inspected jointly by Ofsted and the Care Quality Commission, in addition to their role inspecting providers.
There are no plans to establish a disabled children’s fund. Funding for the National Health Service will grow on average by 3.4% in real terms each year from 2019/20 to 2023/24; by 2023/24 the NHS budget will increase by over £20 billion a year in real terms compared with today.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the announcement by NHS England on 18 December 2017 on new specialised treatments, on which date the Clinical Priorities Advisory Group will meet in May 2018 to consider new recommendations.
Answered by Steve Brine
The Clinical Priorities Advisory Group is meeting on 14, 15 and 16 May to consider new recommendations on specialised treatments.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the announcement by NHS England on 18 December 2017 on new specialised treatments, what estimate he has made of the annual expenditure for new medicines approved for funding as a result of the November 2017 prioritisation process.
Answered by Steve Brine
With reference to the announcement made by NHS England on 18 December 2017 on new specialised treatments for funding as a result of the November 2017 prioritisation process, NHS England estimate that in excess of £3 million annual expenditure for new medicines was approved.
Asked by: Crispin Blunt (Independent - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance is issued by NHS England to manufacturers on the negotiation of medical outcomes-based commercial agreements for products undergoing review by the specialised commissioning prioritisation process.
Answered by Steve Brine
The published guidance about the specialised commissioning clinical prioritisation process is published on the NHS England website. This can be found here at:
https://www.england.nhs.uk/wp-content/uploads/2017/09/spec-comm-service-development-policy.pdf
Where a product is already in scope of a framework tender process run by the commercial medicines unit instructions on offer submissions are provided via the standard supplier portal as part of the tender process in the usual way. No general guidance has been issued to manufacturers.